HUP0001262A2 - 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one deriatives, their preparation and their use as dopamine autoreceptor (d2) agonists - Google Patents
4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one deriatives, their preparation and their use as dopamine autoreceptor (d2) agonistsInfo
- Publication number
- HUP0001262A2 HUP0001262A2 HU0001262A HUP0001262A HUP0001262A2 HU P0001262 A2 HUP0001262 A2 HU P0001262A2 HU 0001262 A HU0001262 A HU 0001262A HU P0001262 A HUP0001262 A HU P0001262A HU P0001262 A2 HUP0001262 A2 HU P0001262A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- hydrogen atom
- alkyl group
- agonists
- alkyl
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title abstract 4
- 102000007527 Autoreceptors Human genes 0.000 title abstract 2
- 108010071131 Autoreceptors Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 229960003638 dopamine Drugs 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- -1 1,2,3,4-tetrahydroquinolin-1-yl Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 150000004703 alkoxides Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány (I) általános képletű vegyületekre vonatkozik - ahol R1 jelentése hidrogénatom vagy 1-6 szénatomos alkilcsoport; R2 jelentése hidrogénatom, egyenes vagy elágazú láncú 1-10 szénatomosalkilcsoport, ciklohexil-metil- vagy -(CH2)mAr, ahol Ar jelentéseadott esetben egy vagy két 1-6 szénatomos alkilcsoporttal,halogénatommal, 1-6 szénatomos alkoxiddal vagy trifluor-metil-csoporttal szubsztituált fenil-, naftil-, tienil-, furanil- vagypiridinilcsoport, vagy NR1R2 jelentése 1,2,3,4-tetrahidrokinolin-1-il- vagy 1,2,3,4-tetrahidroizokinolin-2-il-csoport; m értéke 1-5; n értéke 1 vagy 2; R3 jelentése hidrogénatom vagy 1-6 szénatomos alkilcsoport; Y jelentése halogénatom, 1-6 szénatomos alkil- vagy 1-6 szénatomosalkoxicsoport. A találmány kiterjed a vegyületek gyógyászatilagelfogadható sóira, és a vegyületek dopaminautoreceptor-agonisták, ésmint ilyenek, skizofrénia, Parkinson-kór, Tourette-szindróma, alkohol-és gyógyszerfüggőség kezelésére alkalmasak. ÓThe invention relates to compounds of general formula (I) - where R1 is a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; R2 is a hydrogen atom, a straight or branched C1-C10 alkyl group, cyclohexylmethyl- or -(CH2)mAr, where Ar is optionally with one or two C1-6 alkyl groups, a halogen atom, a C1-6 alkoxide or a trifluoromethyl group substituted phenyl, naphthyl, thienyl, furanyl or pyridinyl, or NR1R2 is 1,2,3,4-tetrahydroquinolin-1-yl or 1,2,3,4-tetrahydroisoquinolin-2-yl; value of m is 1-5; n is 1 or 2; R3 is a hydrogen atom or a C1-C6 alkyl group; Y is a halogen atom, a C1-C6 alkyl or a C1-C6 alkoxy group. The invention covers the pharmaceutically acceptable salts of the compounds, and the compounds are dopamine autoreceptor agonists and, as such, are suitable for the treatment of schizophrenia, Parkinson's disease, Tourette's syndrome, alcohol and drug addiction. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80187097A | 1997-02-18 | 1997-02-18 | |
| PCT/US1998/000623 WO1998035946A1 (en) | 1997-02-18 | 1998-01-13 | 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one derivatives, their preparation and their use as dopamine autoreceptor (d2) agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0001262A2 true HUP0001262A2 (en) | 2001-04-28 |
| HUP0001262A3 HUP0001262A3 (en) | 2002-04-29 |
Family
ID=25182225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001262A HUP0001262A3 (en) | 1997-02-18 | 1998-01-13 | 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one deriatives, their preparation and their use as dopamine autoreceptor (d2) agonists |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0964853A1 (en) |
| JP (1) | JP2001511804A (en) |
| KR (1) | KR20000071160A (en) |
| CN (1) | CN1138761C (en) |
| AR (1) | AR011138A1 (en) |
| AU (1) | AU744443B2 (en) |
| BR (1) | BR9807703A (en) |
| CA (1) | CA2278747A1 (en) |
| HU (1) | HUP0001262A3 (en) |
| IL (1) | IL131156A0 (en) |
| NZ (1) | NZ337271A (en) |
| TW (1) | TW383303B (en) |
| WO (1) | WO1998035946A1 (en) |
| ZA (1) | ZA981310B (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE914003A1 (en) * | 1990-11-20 | 1992-05-20 | Astra Pharma Prod | Biologically Active Amines |
| GB9210632D0 (en) * | 1992-05-19 | 1992-07-01 | Fisons Plc | Compounds |
| EP1123933A1 (en) * | 1994-10-14 | 2001-08-16 | MERCK PATENT GmbH | 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent |
| IL119483A (en) * | 1995-11-06 | 1999-06-20 | American Home Prod | 2-(Aminomethyl)-3,4,7,9- tetrahydro- 2H-pyrano-2[3,3-e]indol-8-ones their derivatives and pharmaceutical compositions containing them |
| JP2000516959A (en) * | 1996-08-27 | 2000-12-19 | アメリカン・ホーム・プロダクツ・コーポレイション | 4-aminoethoxyindolone derivative |
| JP2000517318A (en) * | 1996-08-27 | 2000-12-26 | アメリカン・ホーム・プロダクツ・コーポレイション | 4-Aminoethoxyindolones as dopamine D2 agonists |
-
1998
- 1998-01-13 KR KR1019997007450A patent/KR20000071160A/en not_active Application Discontinuation
- 1998-01-13 IL IL13115698A patent/IL131156A0/en unknown
- 1998-01-13 JP JP53572998A patent/JP2001511804A/en active Pending
- 1998-01-13 CA CA002278747A patent/CA2278747A1/en not_active Abandoned
- 1998-01-13 EP EP98903469A patent/EP0964853A1/en not_active Withdrawn
- 1998-01-13 AU AU60234/98A patent/AU744443B2/en not_active Ceased
- 1998-01-13 HU HU0001262A patent/HUP0001262A3/en unknown
- 1998-01-13 CN CNB988041197A patent/CN1138761C/en not_active Expired - Fee Related
- 1998-01-13 WO PCT/US1998/000623 patent/WO1998035946A1/en not_active Application Discontinuation
- 1998-01-13 BR BR9807703-1A patent/BR9807703A/en not_active IP Right Cessation
- 1998-01-13 NZ NZ337271A patent/NZ337271A/en unknown
- 1998-02-05 TW TW087101495A patent/TW383303B/en not_active IP Right Cessation
- 1998-02-11 AR ARP980100620A patent/AR011138A1/en not_active Application Discontinuation
- 1998-02-17 ZA ZA9801310A patent/ZA981310B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998035946A1 (en) | 1998-08-20 |
| KR20000071160A (en) | 2000-11-25 |
| ZA981310B (en) | 1999-08-17 |
| TW383303B (en) | 2000-03-01 |
| CN1138761C (en) | 2004-02-18 |
| EP0964853A1 (en) | 1999-12-22 |
| NZ337271A (en) | 2001-01-26 |
| AU6023498A (en) | 1998-09-08 |
| AR011138A1 (en) | 2000-08-02 |
| BR9807703A (en) | 2000-05-02 |
| JP2001511804A (en) | 2001-08-14 |
| AU744443B2 (en) | 2002-02-21 |
| CN1252060A (en) | 2000-05-03 |
| CA2278747A1 (en) | 1998-08-20 |
| HUP0001262A3 (en) | 2002-04-29 |
| IL131156A0 (en) | 2001-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0002112A2 (en) | Substituted 3-cyano quinolines, process for producing them and use of them and pharmaceutical compositions containing them | |
| HUP0402507A2 (en) | Novel n(phenylsulfonyl)glycine derivatives, their use and pharmaceutical compositions containing them | |
| HUP9802937A2 (en) | Benzo[g]quuinoline derivatives, pharmaceutical compositions containing them and their use | |
| SE0104334D0 (en) | Therapeutic agents | |
| HUP9700992A2 (en) | 3-(piperid-4-yl)1,2-benzisoxazole and 3-(piperazin-4-yl)-1,2-benzisoxazole compounds, process for their preparation and pharmaceutical compositions containing them | |
| HUP0401086A2 (en) | 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for preparation of pharmaceutical compositions for the treatment of pain, anxiety or gastrointestinal disorders and process for preparation the compounds | |
| HUP0401729A2 (en) | Alkyne-aryl-naphthyridin-4(1h)-one derivaties as phosphodiesterase-4 inhibitors and pharmaceutical compositions containing them | |
| HUP9903971A1 (en) | Use of isoflavones for producing pharmaceutical compositions against menopausal syndrome | |
| HUP0302943A2 (en) | New heterocyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents | |
| DE69823648D1 (en) | 1-PHENYL-4-BENZYLPIPERAZINE: SPECIFIC LIGANDS FOR THE DOPAMINE RECEPTOR (D4) | |
| HUP0402235A2 (en) | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivatives or salts thereof, and pharmaceutical compositions containing them | |
| HUP0401638A2 (en) | Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same | |
| HUP0100865A2 (en) | Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists, pharmaceutical compositions comprising thereof and their use | |
| HUP0401235A2 (en) | Arylsulfonyl derivatives with 5-ht6 receptor affinity, process for producing them and pharmaceutical compositions containing them | |
| HUP0401883A2 (en) | Muscarinic agonists and pharmaceutical compositions containing them | |
| AR035451A1 (en) | DERIVATIVES OF BETA-CARBOLINA, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DEPRESSION, ANXIETY AND BIPOLAR DISORDERS, A PHARMACEUTICAL COMPOSITION AND A COMBINATION. | |
| HUP0101469A2 (en) | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as alpha-adrenoceptor agonists with improved metabolic stability | |
| HUP0402602A2 (en) | Method for preparing echinocandin derivatives, their use, pharmaceutical compositions comprising thereof and their intermediates | |
| HUP0402515A2 (en) | Novel substituted n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1h-pyrazole-5-carboxamides as inhibitors of factor xa, their use and pharmaceutical compositions containing them | |
| HUP0303361A2 (en) | Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them | |
| HUP0402341A2 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
| HUP0104701A2 (en) | 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders and medicaments containing the compounds | |
| HUP0105426A2 (en) | Derivatives of 3-(2-oxo-[1,3']bipyrrolidinyl-3-ylidenemethyl)-cephems and pharmaceutical compositions thereof | |
| HUP9904284A2 (en) | Process for preparation of physostigmine carbamate derivatives | |
| HUP0001262A2 (en) | 4-aminoalkoxy-1,3-dihydrobenzoimidazol-2-one deriatives, their preparation and their use as dopamine autoreceptor (d2) agonists |